Jennifer Peppe - 12 Jan 2022 Form 4 Insider Report for Imago BioSciences, Inc.

Role
Senior Vice President, Clinical Operations
Signature
/s/ Hugh Rienhoff, as Attorney-in-fact for Jennifer Peppe
Issuer symbol
N/A
Transactions as of
12 Jan 2022
Net transactions value
-$254,294
Form type
4
Filing time
14 Jan 2022, 17:48:18 UTC
Previous filing
19 Nov 2021
Next filing
09 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGO Common Stock Options Exercise $6,517 +2,976 +2% $2.19* 151,785 12 Jan 2022 Direct F1
transaction IMGO Common Stock Options Exercise $5,403 +2,380 +1.6% $2.27* 154,165 12 Jan 2022 Direct F1
transaction IMGO Common Stock Options Exercise $13,139 +8,644 +5.6% $1.52* 162,809 12 Jan 2022 Direct F1
transaction IMGO Common Stock Sale $279,353 -14,000 -8.6% $19.95 148,809 12 Jan 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGO Stock Option (Right to Buy) Options Exercise $0 -2,976 -100% $0.000000* 0 12 Jan 2022 Common Stock 2,976 $2.19 Direct F1
transaction IMGO Stock Option (Right to Buy) Options Exercise $0 -2,380 -100% $0.000000* 0 12 Jan 2022 Common Stock 2,380 $2.27 Direct F1
transaction IMGO Stock Option (Right to Buy) Options Exercise $0 -8,644 -26% $0.000000 24,094 12 Jan 2022 Common Stock 8,644 $1.52 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The transaction was executed in multiple trades in prices ranging from $19.62 to $20.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from April 10, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Senior Vice President, Clinical Operations